You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCilazapril
Accession NumberDB01340
TypeSmall Molecule
GroupsApproved
DescriptionCilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.
Structure
Thumb
Synonyms
Cilazapril
Cilazapril anhydrous
Cilazaprilum
External Identifiers
  • Ro 31-2848
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CilazaprilTablet2.5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
CilazaprilTablet5.0 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
CilazaprilTablet5 mgOralSanis Health Inc2010-05-312014-08-01Canada
CilazaprilTablet1 mgOralSanis Health Inc2010-05-31Not applicableCanada
CilazaprilTablet1.0 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
CilazaprilTablet2.5 mgOralSanis Health Inc2010-05-31Not applicableCanada
Co CilazaprilTablet2.5 mgOralCobalt Pharmaceuticals Company2007-02-06Not applicableCanada
Co CilazaprilTablet5.0 mgOralCobalt Pharmaceuticals Company2007-02-06Not applicableCanada
Co CilazaprilTablet1.0 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Dom-cilazaprilTablet2.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazaprilTablet5.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazaprilTablet1.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Inhibace Tab 1mgTablet1 mgOralHoffmann La Roche Limited1993-12-312010-07-21Canada
Inhibace Tab 2.5mgTablet2.5 mgOralHoffmann La Roche Limited1993-12-31Not applicableCanada
Inhibace Tab 5mgTablet5 mgOralHoffmann La Roche Limited1993-12-31Not applicableCanada
Mylan-cilazaprilTablet5.0 mgOralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Mylan-cilazaprilTablet1 mgOralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Mylan-cilazaprilTablet2.5 mgOralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Ntp-cilazaprilTablet1 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-cilazaprilTablet2.5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-cilazaprilTablet5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
PHL-cilazaprilTablet2.5 mgOralPharmel Inc2008-10-30Not applicableCanada
PHL-cilazaprilTablet5.0 mgOralPharmel Inc2008-10-30Not applicableCanada
PHL-cilazaprilTablet1.0 mgOralPharmel Inc2008-10-30Not applicableCanada
PMS-cilazaprilTablet5.0 mgOralPharmascience Inc2006-06-09Not applicableCanada
PMS-cilazaprilTablet1.0 mgOralPharmascience Inc2006-06-09Not applicableCanada
PMS-cilazaprilTablet2.5 mgOralPharmascience Inc2006-06-09Not applicableCanada
Teva-cilazaprilTablet5 mgOralTeva Canada Limited2005-04-01Not applicableCanada
Teva-cilazaprilTablet1 mgOralTeva Canada Limited2005-04-01Not applicableCanada
Teva-cilazaprilTablet2.5 mgOralTeva Canada Limited2005-04-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cilazaprilTablet1 mgOralApotex Inc2007-02-01Not applicableCanada
Apo-cilazaprilTablet2.5 mgOralApotex Inc2007-02-01Not applicableCanada
Apo-cilazaprilTablet5 mgOralApotex Inc2007-02-01Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DynormRoche
InhibaceRoche
InhibestrilTeva
VascaceRoche
ZaprilMylan
ZoboxHemofarm
Brand mixtures
NameLabellerIngredients
Apo-cilazapril/hctzApotex Inc
Inhibace Plus - TabHoffmann La Roche Limited
Novo-cilazapril/hctzTeva Canada Limited
Salts
Name/CASStructureProperties
Cilazapril monohydrate
92077-78-6
Thumb
  • InChI Key: JQRZBPFGBRIWSN-YOTVLOEGSA-N
  • Monoisotopic Mass: 435.236935795
  • Average Mass: 435.521
DBSALT001097
Categories
UNII8Q9454114Q
CAS number88768-40-5
WeightAverage: 417.4986
Monoisotopic: 417.226371117
Chemical FormulaC22H31N3O5
InChI KeyHHHKFGXWKKUNCY-FHWLQOOXSA-N
InChI
InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
IUPAC Name
(1S,9S)-9-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxo-octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CCCN2CCC[[email protected]](N2C1=O)C(O)=O
Pharmacology
IndicationCilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.
Structured Indications
PharmacodynamicsCilazapril inhibits the production angiotensin II. By doing so, it decreases sodium and water reabsorption (via aldosterone) and it decreases vasoconstriction. The combined effect of this is a decrease in vascular resistance, and therefore, blood pressure. The absolute bioavailability of cilazaprilat after oral administration of cilazapril is 57% based on urinary recovery data. (The absolute bioavailability of cilazaprilat after oral administration of cilazaprilat is 19%.) Ingestion of food immediately before the administration of cilazapril reduces the average peak plasma concentration of cilazaprilat by 29%, delays the peak by one hour and reduces the bioavailability of cilazaprilat by 14%. These pharmacokinetic changes have little influence on plasma ACE inhibition.
Mechanism of actionCilazapril is a pyridazine ACE inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
AbsorptionMaximum plasma concentrations of cilazaprilat are reached within two hours after administration of cilazapril.
Volume of distributionNot Available
Protein bindingMaximum ACE inhibition is greater than 90% after 1 to 5 mg cilazapril. Maximum ACE inhibition is 70 to 80% after 0.5 mg cilazapril. Dose proportionality is observed following the administration of 1 to 5 mg cilazapril. Apparent non-proportionality is observed at 0.5 mg reflective of the binding to ACE. The higher doses of cilazapril are associated with longer duration of maximum ACE inhibition.
Metabolism
SubstrateEnzymesProduct
Cilazapril
Not Available
CilazaprilatDetails
Route of eliminationCilazaprilat is eliminated unchanged by the kidneys. The total urinary recovery of cilazaprilat after intravenous administration of 2.5 mg is 91%.
Half lifeHalf-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.
Clearance

Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.

ToxicityLimited data are available with regard to overdosage in humans. The most likely manifestations are hypotension, which may be severe, hyperkalaemia, hyponatraemia and renal impairment with metabolic acidosis. Treatment should be mainly symptomatic and supportive.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Cilazapril Metabolism PathwayDrug metabolismSMP00592
Cilazapril Action PathwayDrug actionSMP00147
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Cilazapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Cilazapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cilazapril.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Cilazapril.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Cilazapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cilazapril.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Cilazapril.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Cilazapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Cilazapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Cilazapril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cilazapril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Cilazapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Cilazapril.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cilazapril.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Cilazapril.Experimental
AmifostineCilazapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Cilazapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Cilazapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Cilazapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Cilazapril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cilazapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Cilazapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Cilazapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Antipyrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Cilazapril.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Cilazapril.Approved
ApremilastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Cilazapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Cilazapril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Cilazapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Cilazapril is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Cilazapril.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Cilazapril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Cilazapril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cilazapril.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Cilazapril.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azapropazone.Withdrawn
AzathioprineCilazapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Cilazapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Cilazapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Cilazapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Cilazapril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Cilazapril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cilazapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Cilazapril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Benoxaprofen.Withdrawn
BepridilBepridil may increase the hypotensive activities of Cilazapril.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Cilazapril.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Cilazapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Cilazapril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Betulinic Acid.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cilazapril.Approved
BoceprevirThe serum concentration of Cilazapril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Cilazapril.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cilazapril.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cilazapril.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Cilazapril.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Cilazapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Cilazapril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Cilazapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cilazapril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bupivacaine.Approved, Investigational
BupranololCilazapril may increase the hypotensive activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Cilazapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Cilazapril.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Cilazapril.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Cilazapril.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Cilazapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Cilazapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Cilazapril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Cilazapril.Approved
CarbamazepineThe metabolism of Cilazapril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Cilazapril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Cilazapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Cilazapril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Cilazapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Celecoxib.Approved, Investigational
CeliprololCilazapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Cilazapril.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cilazapril.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Cilazapril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cilazapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Cilazapril.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Cilazapril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Cilazapril.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Cilazapril.Approved, Investigational
CiprofloxacinCilazapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cilazapril.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Cilazapril.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Cilazapril.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilazapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Cilazapril.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Cilazapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Cilazapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cilazapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Cilazapril.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Cilazapril.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cilazapril.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cilazapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Cilazapril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Cilazapril.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Cilazapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Cilazapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Cilazapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilazapril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Cilazapril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Cilazapril is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Cilazapril.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Cilazapril.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Cilazapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Cilazapril.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Cilazapril.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Cilazapril.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Cilazapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Cilazapril.Investigational
DeserpidineCilazapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Cilazapril.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cilazapril.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Cilazapril.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Cilazapril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Cilazapril.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Cilazapril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cilazapril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Cilazapril.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Cilazapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cilazapril.Approved
DihydralazineCilazapril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilazapril.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Cilazapril.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Cilazapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Cilazapril.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Cilazapril.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Cilazapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Cilazapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Cilazapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Cilazapril.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cilazapril.Approved, Investigational
DrospirenoneCilazapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Droxicam.Approved
DuloxetineCilazapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Cilazapril.Approved
E6201The risk or severity of adverse effects can be increased when Cilazapril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ebselen.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cilazapril.Approved
EfonidipineCilazapril may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cilazapril.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Cilazapril.Approved, Vet Approved
EnalaprilatCilazapril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Cilazapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Cilazapril.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cilazapril.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Cilazapril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Cilazapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Cilazapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Cilazapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Cilazapril.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Cilazapril.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Cilazapril.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Cilazapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Cilazapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Cilazapril.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Cilazapril.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Cilazapril.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Cilazapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Cilazapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilazapril.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cilazapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Cilazapril.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Cilazapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cilazapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Cilazapril is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Cilazapril.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Cilazapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Cilazapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cilazapril.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Cilazapril.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cilazapril.Approved
FimasartanThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Cilazapril.Approved
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Cilazapril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cilazapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Cilazapril.Approved, Vet Approved
GarlicThe serum concentration of Cilazapril can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Cilazapril.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Cilazapril.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cilazapril.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Cilazapril.Withdrawn
GuanabenzGuanabenz may increase the hypotensive activities of Cilazapril.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Cilazapril.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Cilazapril.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cilazapril.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Cilazapril.Approved
HalothaneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
HexamethoniumCilazapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Cilazapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Cilazapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Cilazapril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Cilazapril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Cilazapril.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cilazapril.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Cilazapril.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cilazapril.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Cilazapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Cilazapril.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Cilazapril.Approved
IloprostIloprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Cilazapril.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cilazapril.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cilazapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cilazapril.Approved
IndenololCilazapril may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Cilazapril.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Cilazapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indoprofen.Withdrawn
IndoraminCilazapril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Cilazapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Cilazapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Cilazapril.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Cilazapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cilazapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilazapril.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Cilazapril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Cilazapril.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Cilazapril.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Kebuzone.Experimental
KetanserinCilazapril may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Cilazapril.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Cilazapril.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Cilazapril.Approved
LacidipineCilazapril may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cilazapril.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cilazapril.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Cilazapril.Approved, Investigational
Lanthanum carbonateThe serum concentration of Cilazapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cilazapril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Cilazapril.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Cilazapril.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cilazapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cilazapril.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Levobupivacaine.Approved
LevodopaCilazapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Cilazapril.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Cilazapril.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Cilazapril is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Cilazapril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cilazapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Cilazapril.Approved
LofexidineCilazapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Cilazapril.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Cilazapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cilazapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lumiracoxib.Approved, Investigational
MacitentanCilazapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Magnesium salicylate.Approved
ManidipineCilazapril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Cilazapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Cilazapril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Cilazapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Cilazapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Cilazapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Cilazapril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Cilazapril.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Cilazapril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cilazapril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Cilazapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Cilazapril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cilazapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Cilazapril.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cilazapril.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cilazapril.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Cilazapril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Cilazapril.Approved, Investigational
MetyrosineCilazapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilCilazapril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cilazapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Cilazapril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Cilazapril.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cilazapril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Cilazapril.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Cilazapril.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Cilazapril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Cilazapril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Cilazapril.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Cilazapril.Approved, Investigational
MoxonidineCilazapril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cilazapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Cilazapril.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Cilazapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naftifine.Approved
NaftopidilCilazapril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cilazapril.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Cilazapril.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Cilazapril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Cilazapril.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Cilazapril.Approved
NepafenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Cilazapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Cilazapril.Approved
NicorandilNicorandil may increase the hypotensive activities of Cilazapril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilazapril.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Niflumic Acid.Approved
NiguldipineCilazapril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Cilazapril.Approved, Investigational
NilvadipineCilazapril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Cilazapril.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cilazapril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Cilazapril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Cilazapril.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Cilazapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Cilazapril.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Cilazapril.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cilazapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Cilazapril.Approved
ObinutuzumabCilazapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Cilazapril.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Cilazapril.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Cilazapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Cilazapril.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Cilazapril.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Cilazapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Cilazapril.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxaprozin.Approved
OxprenololCilazapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Cilazapril.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Cilazapril.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Cilazapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Cilazapril.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cilazapril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Cilazapril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Cilazapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cilazapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Cilazapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Cilazapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Cilazapril.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Cilazapril.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Cilazapril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cilazapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Cilazapril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cilazapril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cilazapril.Approved
PinacidilCilazapril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Cilazapril.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Cilazapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Cilazapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cilazapril.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Cilazapril.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Cilazapril.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Cilazapril.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Cilazapril.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cilazapril.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Cilazapril.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Cilazapril.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Cilazapril.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Cilazapril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Cilazapril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Cilazapril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cilazapril.Approved
PTC299The risk or severity of adverse effects can be increased when Cilazapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Cilazapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Cilazapril.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cilazapril.Approved
QuinineQuinine may increase the hypotensive activities of Cilazapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Cilazapril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Cilazapril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cilazapril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Cilazapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Cilazapril.Approved
RescinnamineCilazapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cilazapril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Cilazapril.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cilazapril.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cilazapril.Approved, Investigational
RilmenidineCilazapril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Cilazapril.Approved
RisperidoneCilazapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Cilazapril.Approved, Investigational
RituximabCilazapril may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Cilazapril.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Rofecoxib.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Cilazapril.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cilazapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Cilazapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Cilazapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Cilazapril.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cilazapril.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Cilazapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Cilazapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Cilazapril.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Cilazapril.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Cilazapril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cilazapril.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Cilazapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cilazapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cilazapril.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Cilazapril.Approved, Investigational
SitaxentanCilazapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Cilazapril.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Cilazapril.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Cilazapril.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cilazapril.Experimental
SpiraprilCilazapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Cilazapril.Approved
SRT501The risk or severity of adverse effects can be increased when Cilazapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Cilazapril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Cilazapril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Cilazapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cilazapril.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Cilazapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Cilazapril.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Cilazapril.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Cilazapril.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Cilazapril.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cilazapril.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Cilazapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Cilazapril.Approved, Investigational
TemocaprilCilazapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Cilazapril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Cilazapril.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Teriflunomide.Approved
TerlipressinCilazapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Cilazapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Cilazapril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tiaprofenic acid.Approved
TiboloneCilazapril may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cilazapril.Approved
TicrynafenCilazapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Cilazapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Cilazapril.Approved
TipranavirThe serum concentration of Cilazapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Cilazapril.Approved
TolazolineTolazoline may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Cilazapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Cilazapril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cilazapril.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Cilazapril.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Cilazapril.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cilazapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cilazapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Cilazapril.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Cilazapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Cilazapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Cilazapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Cilazapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Cilazapril.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
TrimazosinCilazapril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Cilazapril.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Cilazapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Cilazapril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Cilazapril.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cilazapril.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cilazapril.Approved
UnoprostoneCilazapril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Cilazapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Cilazapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Cilazapril.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Cilazapril.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Cilazapril.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Cilazapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Cilazapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cilazapril.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Cilazapril.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cilazapril.Approved, Investigational
VinpocetineCilazapril may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Cilazapril.Approved
XylometazolineCilazapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Cilazapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Cilazapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Food decreases cilazapril absorption with no significant clinical impact.
  • Take without regard to meals.
References
Synthesis Reference

Attwood, M. R.; Hassall, C. H.; Kr�Hn, A.; Lawton, G.; Redshaw, S. (1986). “The design and synthesis of the Angiotensin Converting Enzyme inhibitor Cilazapril and related bicyclic compounds”. Journal of the Chemical Society, Perkin Transactions 1: 1011. doi:10.1039/P19860001011

US20060293517
General References
  1. Fasanella d'Amore T, Bussien JP, Nussberger J, Waeber B, Turini GA, Brunner HR, Kler L, Francis RJ: Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol. 1987 Jan;9(1):26-31. [PubMed:2434790 ]
External Links
ATC CodesC09BA08C09AA08
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSDownload (81.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier-0.9402
Caco-2 permeable-0.7698
P-glycoprotein substrateSubstrate0.8727
P-glycoprotein inhibitor IInhibitor0.7775
P-glycoprotein inhibitor IINon-inhibitor0.8788
Renal organic cation transporterNon-inhibitor0.8318
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.8283
CYP450 3A4 substrateSubstrate0.5396
CYP450 1A2 substrateNon-inhibitor0.882
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.7503
CYP450 2C19 inhibitorNon-inhibitor0.816
CYP450 3A4 inhibitorNon-inhibitor0.8201
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8376
Ames testNon AMES toxic0.6023
CarcinogenicityNon-carcinogens0.9028
BiodegradationNot ready biodegradable0.9942
Rat acute toxicity2.3700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9311
hERG inhibition (predictor II)Inhibitor0.6303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral
TabletOral2.5 mg
TabletOral5 mg
TabletOral1 mg
TabletOral1.0 mg
TabletOral5.0 mg
Prices
Unit descriptionCostUnit
Inhibace 5 mg Tablet0.94USD tablet
Inhibace 2.5 mg Tablet0.81USD tablet
Inhibace 1 mg Tablet0.7USD tablet
Apo-Cilazapril 5 mg Tablet0.52USD tablet
Co Cilazapril 5 mg Tablet0.52USD tablet
Mylan-Cilazapril 5 mg Tablet0.52USD tablet
Novo-Cilazapril 5 mg Tablet0.52USD tablet
Pms-Cilazapril 5 mg Tablet0.52USD tablet
Apo-Cilazapril 2.5 mg Tablet0.45USD tablet
Co Cilazapril 2.5 mg Tablet0.45USD tablet
Mylan-Cilazapril 2.5 mg Tablet0.45USD tablet
Novo-Cilazapril 2.5 mg Tablet0.45USD tablet
Pms-Cilazapril 2.5 mg Tablet0.45USD tablet
Apo-Cilazapril 1 mg Tablet0.39USD tablet
Mylan-Cilazapril 1 mg Tablet0.39USD tablet
Novo-Cilazapril 1 mg Tablet0.39USD tablet
Pms-Cilazapril 1 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20060293517 No2004-03-082024-03-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point98 ºC with decomposition Not Available
water solubilityWater (25 ºC) 0.5 g/100 mL Not Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.06 mg/mLALOGPS
logP-0.2ALOGPS
logP-0.0079ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)5.35ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity110.56 m3·mol-1ChemAxon
Polarizability44.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acid ester
  • Diazepane
  • 1,2-diazepane
  • Fatty acyl
  • Benzenoid
  • Pyridazine
  • Dicarboxylic acid or derivatives
  • 1,2-diazinane
  • Monocyclic benzene moiety
  • Carboxylic acid hydrazide
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, Yoshikawa J: Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension. 1999 Apr;33(4):961-8. [PubMed:10205231 ]
  2. Kihara M, Mitsui MK, Mitsui Y, Okuda K, Nakasaka Y, Takahashi M, Schmelzer JD: Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve. 1999 Jul;22(7):920-5. [PubMed:10398211 ]
  3. Mervaala E, Dehmel B, Gross V, Lippoldt A, Bohlender J, Milia AF, Ganten D, Luft FC: Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol. 1999 Aug;10(8):1669-80. [PubMed:10446934 ]
  4. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157 ]
  5. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161 ]
  6. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18. [PubMed:18423812 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:09 / Updated on August 17, 2016 12:23